Active Ingredient/Content
|
Efficacy/Indication
- Treatment of the following mild to moderate infections caused by susceptible isolates of bacteria: Pharyngitis/tonsillitis, acute maxillary sinusitis, community-acquired pneumonia (CAP), uncomplicated skin and skin structure infections (SSSIs), and disseminated mycobacterial infections, et al.
|
Administration/Dosage
- - Mycobacterial Infections : 500mg bid
- - Skin and Skin Structure Infections,Uncomplicated Infections due to Staphylococcus aureus or Streptococcus pyogenes: 250mg q12h for 7-14 days
|